VERSACLOZ
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VERSACLOZ (VERSACLOZ).
Clozapine is an atypical antipsychotic that binds to dopamine D4 and serotonin 5-HT2A receptors with high affinity, and also to D1, D2, D3, D5, 5-HT1A, 5-HT1C, 5-HT3, 5-HT6, 5-HT7, alpha-adrenergic, histamine H1, and muscarinic M1-M5 receptors.
| Metabolism | Primarily metabolized by CYP1A2, with minor contributions from CYP2C9, CYP2D6, and CYP3A4. |
| Excretion | Renal: ~50% (30% as unchanged drug, rest as metabolites); fecal: ~30% (via bile); minor biliary elimination. |
| Half-life | Terminal elimination half-life ~12 hours (range 6-33 hours); steady-state achieved within 7-10 days; requires gradual dose titration to mitigate seizure risk. |
| Protein binding | ~97% primarily to albumin and α1-acid glycoprotein. |
| Volume of Distribution | Vd ~5.0 L/kg (range 4-7 L/kg); indicates extensive extravascular tissue distribution, including CNS. |
| Bioavailability | Oral: ~87% (range 50-90%); minimal first-pass effect; absorption unaffected by food. |
| Onset of Action | Oral: 2-3 weeks for antipsychotic effect; maximal improvement by 6-12 months. |
| Duration of Action | Sustained after steady-state; once-daily dosing due to half-life; therapeutic effect persists for days to weeks after discontinuation. |
Initial: 12.5 mg orally once or twice daily; titrate by 25-50 mg/day to target dose of 300-450 mg/day divided, with maximum 900 mg/day.
| Dosage form | SUSPENSION |
| Renal impairment | No dose adjustment required for mild-to-moderate renal impairment. Use caution in severe renal impairment (eGFR <30 mL/min); consider dose reduction or increased monitoring. |
| Liver impairment | Child-Pugh Class A: no adjustment needed. Child-Pugh Class B: use 50% of usual dose. Child-Pugh Class C: contraindicated due to risk of accumulation and hepatotoxicity. |
| Pediatric use | Not approved for use in patients <18 years; safety and efficacy not established. |
| Geriatric use | Start at 12.5 mg once daily; titrate slowly (increase by 12.5-25 mg/day) due to increased sensitivity and risk of hypotension, sedation, and anticholinergic effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VERSACLOZ (VERSACLOZ).
| Breastfeeding | Clozapine is excreted into breast milk with a reported M/P ratio of approximately 2.8 (range 1.7–4.3). Infant doses range from 0.1% to 0.5% of maternal weight-adjusted dose. Adverse effects observed include drowsiness, lethargy, poor sucking, and agranulocytosis risk; therefore, breastfeeding is generally not recommended. |
| Teratogenic Risk | First trimester: Limited human data; animal studies show no teratogenic effects at clinically relevant doses. Risk cannot be excluded. Second and third trimesters: Clozapine crosses placenta; case reports of neonatal withdrawal (akathisia, jitteriness, respiratory distress) and floppy infant syndrome with late exposure. No consistent pattern of major malformations. |
■ FDA Black Box Warning
1. Severe Neutropenia: Clozapine can cause severe neutropenia (absolute neutrophil count <500/μL), which may lead to serious infections and death. 2. Orthostatic Hypotension, Bradycardia, Syncope: Especially during initial titration, can be fatal. 3. Seizures: Risk increases with dose; monitor and adjust therapy. 4. Myocarditis and Cardiomyopathy: Can be fatal; discontinue if suspected. 5. Increased Mortality in Elderly Patients with Dementia-Related Psychosis: Not approved for use in this population.
| Serious Effects |
1. History of clozapine-induced agranulocytosis or severe neutropenia. 2. Myeloproliferative disorders. 3. Uncontrolled epilepsy. 4. Severe central nervous system depression or comatose states. 5. Paralytic ileus. 6. Concomitant use with agents known to suppress bone marrow function. 7. Hypersensitivity to clozapine.
| Precautions | 1. Severe Neutropenia: Monitor ANC weekly for first 6 months, then every 2 weeks for 6 months, then monthly; discontinue if ANC <1000/μL. 2. Orthostatic Hypotension, Bradycardia, Syncope: Titrate slowly and monitor vital signs. 3. Seizures: Dose-related; consider reducing dose or adding anticonvulsant. 4. Myocarditis and Cardiomyopathy: Evaluate if symptoms of chest pain, dyspnea, palpitations, or fever occur. 5. Increased Mortality in Elderly with Dementia-Related Psychosis: Not indicated. 6. QT Interval Prolongation: Caution with other QT-prolonging drugs. 7. Metabolic Changes: Hyperglycemia, dyslipidemia, weight gain. 8. Gastrointestinal Hypomotility: Constipation, fecal impaction; monitor and treat. 9. Eosinophilia: Monitor for organ involvement. 10. Neuroleptic Malignant Syndrome (NMS): Discontinue if suspected. 11. Tardive Dyskinesia: Watch for involuntary movements. 12. Rebound Psychosis: Withdrawal emergent psychosis upon abrupt discontinuation. |
Loading safety data…
| Fetal Monitoring | Maternal: Complete blood count (CBC) weekly for first 6 months, then biweekly due to agranulocytosis risk; liver function tests; ECG for QTc interval prolongation; serum clozapine levels (therapeutic range 350–600 ng/mL); glucose and lipid profile. Fetal/neonatal: Ultrasound for growth and anomalies in second trimester; neonatal monitoring for withdrawal symptoms, respiratory depression, and hypotension for 48–72 hours postpartum. |
| Fertility Effects | Clozapine can cause hyperprolactinemia (less frequently than typical antipsychotics), potentially leading to menstrual irregularities, galactorrhea, and reduced fertility in women. In men, it may cause erectile dysfunction, decreased libido, and gynecomastia. These effects are reversible upon dose reduction or discontinuation. |